Quantitative comparison of the neutralizing capacity, immunogenicity and cross-reactivity of anti-TNF-α biologicals and an Infliximab-biosimilar.

Buurman, D J

Quantitative comparison of the neutralizing capacity, immunogenicity and cross-reactivity of anti-TNF-α biologicals and an Infliximab-biosimilar. [electronic resource] - PloS one 2018 - e0208922 p. digital

Publication Type: Journal Article

1932-6203

10.1371/journal.pone.0208922 doi


Adalimumab--administration & dosage
Adult
Aged
Antibodies, Anti-Idiotypic--blood
Antibodies, Monoclonal--administration & dosage
Antibodies, Neutralizing
Biological Products--administration & dosage
Biosimilar Pharmaceuticals--administration & dosage
Certolizumab Pegol--administration & dosage
Cross Reactions--immunology
Etanercept--administration & dosage
Female
Humans
Inflammatory Bowel Diseases--blood
Infliximab--administration & dosage
Male
Middle Aged
Tumor Necrosis Factor-alpha--blood